Headquartered in Danvers, MA, ABIOMED Inc. (ABMD - Free Report) is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart.
Currently, ABIOMED has a Zacks Rank #4 (Sell) but that could change following its third quarter fiscal 2020 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here) the complete list of today’s Zacks #1 Rank stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: ABIOMED reported third-quarter fiscal 2020 earnings per share (EPS) of $1.51, outpacing the Zacks Consensus Estimate of $1.09. The figure surged 55.7% year over year.
Revenues: ABIOMED’s revenues came in at $221.6 million, which lagged the Zacks Consensus Estimate of $227 million. However, the metric improved 10.5% from the prior-year quarter.
Key Stats: U.S. Impella product revenues totaled $185.6 million, showing an increase of 8% year over year. Per management, U.S. patient usage of the Impella heart pumps rose 5% in the quarter.
For fiscal 2020, ABIOMED expects revenues within $846-$877 million, mirroring an increase of 10-14%. This compares to the earlier-projected range of $885-$925 million, calling for an increase of 15-20% year over year.
Check back later for our full write up on this ABIOMED report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>